- Immunization:
- Adult: IM 1mL *2 doses 6-12 months apart
- >1 year: IM 0.5ml *2 doses 6-12 months apart
- At risk population:
-
-
- Chronic liver disease
- HIV infection
- Men who have sex with men
- Injection or non-injection drug use
- Homeless patients
- Working with hepatitis A virus
- Travel in countries with high or intermediate endemic HAV infection
- Pregnancy if at risk for infection or severe outcome from infection during pregnancy
- Setting for exposure, including healthcare settings targeting services to injection or non-injection drugs users or group homes, nonresidential day care facilities for developmentally disabled persons
-
- Post exposure prophylaxis:
- Adult: IM 1ml *1
- >1 year: IM 0.5ml *1
- Adult: IM 1ml *1
- Injection:
- 1440 EU/mL
- 720 EU/0.5mL
- Do not dilute
- > 2 years: Administer in deltoid region
- <2 years: Administer in anterolateral area of the thigh
Inactivated vaccine
It induces antibody formation
- Injection site reaction
- Irritability
- Anorexia
- Fatigue
- Headache
- Fever
- Malaise
- Nausea
- Hypersensitivity to class/components
- Hypersensitivity to neomycin
- Belimumab
Drug Status
Availability | Prescription only |
Pregnancy | Category C unless at risk |
Breastfeeding | Can be used |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Avaxim | 160 U/0.5mL | Pre-Filled Syringe | 1’s | Sanofi Pasteur | Ressourcethica Kenya |
Avaxim Pediatric | 80 U/0.5mL | Pre-Filled Syringe | 1’s | Sanofi Pasteur | Ressourcethica Kenya |
Havrix Adult | 1440 EU/mL | Injection | 1’s | GSK Ltd | GSK Ltd |
Havrix Junior | 720 EU/0.5mL | Injection | 1’s | GSK Ltd | GSK Ltd |